Glactone attracts attention in international journals

Glactone Pharma AB, a project company in P.U.L.S, Sweden’s leading life science incubator, is developing a drug for the treatment of metastasizing castration resistant prostate cancer. Glactone,…

Adenovir Pharma raises MSEK 10 to complete phase II study and prepare for exit

The Swedish pharmaceutical development company Adenovir Pharma has raised SEK 10 million via a rights issue to fund completion of an ongoing clinical phase II study for treatment of infectious eye disease and to prepare for exit. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC).

Glactone Pharma raises 5,5 MSEK

Glactone Pharma AB, a project company in P.U.L.S, Sweden’s leading life science incubator, has recently issued a new round of shares of 5.5 MSEK for the continued development of their novel drug for the treatment of castration resistant prostate cancer.

Share this page

Subscribe

Read more about our Protection of your personal data.